Lynsey J Hamlett1,2, Andrew J McPartlin3, Edward J Maile4, Gareth Webster5, Ric Swindell6, Carl G Rowbottom7, Ananya Choudhury1,3, Adam H Aitkenhead1,2. 1. 1 Manchester Academic Health Science Centre (MAHSC), Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK. 2. 2 Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK. 3. 3 Department of Oncology, The Christie NHS Foundation Trust, Manchester, UK. 4. 4 Oxford University Clinical Academic Graduate School, Medical Sciences Division, John Radcliffe Hospital, Oxford, UK. 5. 5 Hall-Edwards Radiotherapy Research Group, Medical Physics, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK. 6. 6 The Christie NHS Foundation Trust, Manchester, UK. 7. 7 Department of Medical Physics, Clatterbridge Cancer Centre, Liverpool, UK.
Abstract
OBJECTIVE: We investigated possible associations between planned dose-volume parameters and rectal late toxicity in 170 patients having radical prostate cancer radiotherapy. METHODS: For each patient, the rectum was outlined from anorectal junction to sigmoid colon, and rectal dose was parametrized using dose-volume (DVH), dose-surface (DSH) and dose-line (DLH) histograms. Generation of DLHs differed from previous studies in that the rectal dose was parametrized without first unwrapping onto 2-dimensional dose-surface maps. Patient-reported outcomes were collected using a validated Later Effects in Normal Tissues Subjective, Objective, Management and Analytic questionnaire. Associations between dose and toxicity were assessed using a one-sided Mann-Whitney U test. RESULTS: Associations (p < 0.05) were found between equieffective dose (EQD23) and late toxicity as follows: overall toxicity with DVH and DSH at 13-24 Gy; proctitis with DVH and DSH at 25-36 Gy and with DVH, DSH and DLH at 61-67 Gy; bowel urgency with DVH and DSH at 10-20 Gy. None of these associations met statistical significance following the application of a Bonferroni correction. CONCLUSION: Independently confirmed associations between rectal dose and late toxicity remain elusive. Future work to increase the accuracy of the knowledge of the rectal dose, either by accounting for interfraction and intrafraction rectal motion or via stabilization of the rectum during treatment, may be necessary to allow for improved dose-toxicity comparisons. ADVANCES IN KNOWLEDGE: This study is the first to use parametrized DLHs to study associations with patient-reported toxicity for prostate radiotherapy showing that it is feasible to model rectal dose mapping in three dimensions.
OBJECTIVE: We investigated possible associations between planned dose-volume parameters and rectal late toxicity in 170 patients having radical prostate cancer radiotherapy. METHODS: For each patient, the rectum was outlined from anorectal junction to sigmoid colon, and rectal dose was parametrized using dose-volume (DVH), dose-surface (DSH) and dose-line (DLH) histograms. Generation of DLHs differed from previous studies in that the rectal dose was parametrized without first unwrapping onto 2-dimensional dose-surface maps. Patient-reported outcomes were collected using a validated Later Effects in Normal Tissues Subjective, Objective, Management and Analytic questionnaire. Associations between dose and toxicity were assessed using a one-sided Mann-Whitney U test. RESULTS: Associations (p < 0.05) were found between equieffective dose (EQD23) and late toxicity as follows: overall toxicity with DVH and DSH at 13-24 Gy; proctitis with DVH and DSH at 25-36 Gy and with DVH, DSH and DLH at 61-67 Gy; bowel urgency with DVH and DSH at 10-20 Gy. None of these associations met statistical significance following the application of a Bonferroni correction. CONCLUSION: Independently confirmed associations between rectal dose and late toxicity remain elusive. Future work to increase the accuracy of the knowledge of the rectal dose, either by accounting for interfraction and intrafraction rectal motion or via stabilization of the rectum during treatment, may be necessary to allow for improved dose-toxicity comparisons. ADVANCES IN KNOWLEDGE: This study is the first to use parametrized DLHs to study associations with patient-reported toxicity for prostate radiotherapy showing that it is feasible to model rectal dose mapping in three dimensions.
Authors: G J Meijer; M van den Brink; M S Hoogeman; J Meinders; J V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 1999-11-01 Impact factor: 7.038
Authors: Susan L Tucker; Ming Zhang; Lei Dong; Radhe Mohan; Deborah Kuban; Howard D Thames Journal: Int J Radiat Oncol Biol Phys Date: 2006-03-15 Impact factor: 7.038
Authors: Emile N J Th van Lin; Aswin L Hoffmann; Peter van Kollenburg; Jan Willem Leer; Andries G Visser Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: Carlos Vargas; Alvaro Martinez; Larry L Kestin; Di Yan; Inga Grills; Donald S Brabbins; David M Lockman; Jian Liang; Gary S Gustafson; Peter Y Chen; Frank A Vicini; John W Wong Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-01 Impact factor: 7.038
Authors: Oscar Casares-Magaz; Ludvig Paul Muren; Vitali Moiseenko; Stine E Petersen; Niclas Johan Pettersson; Morten Høyer; Joseph O Deasy; Maria Thor Journal: Acta Oncol Date: 2017-09-08 Impact factor: 4.089
Authors: L E A Shelley; J E Scaife; M Romanchikova; K Harrison; J R Forman; A M Bates; D J Noble; R Jena; M A Parker; M P F Sutcliffe; S J Thomas; N G Burnet Journal: Radiother Oncol Date: 2017-04-28 Impact factor: 6.280